{"id":"fremanezumab-prefilled-syringe","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Injection site reactions"},{"rate":"5-8","effect":"Nasopharyngitis"},{"rate":"3-5","effect":"Upper respiratory tract infection"},{"rate":"2-4","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL4297756","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CGRP is released during migraine attacks and contributes to pain signaling and neuroinflammation. By binding to and neutralizing CGRP, fremanezumab prevents its interaction with CGRP receptors on sensory neurons and blood vessels, thereby reducing migraine frequency and severity. This mechanism has been shown to be effective in both episodic and chronic migraine prevention.","oneSentence":"Fremanezumab is a monoclonal antibody that blocks calcitonin gene-related peptide (CGRP), a neuropeptide involved in migraine pathogenesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:39:51.092Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Episodic migraine prevention"},{"name":"Chronic migraine prevention"}]},"trialDetails":[{"nctId":"NCT04693533","phase":"PHASE4","title":"Fremanezumab, Migraine and Sleep","status":"TERMINATED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2021-07-29","conditions":"Migraine Disorders, Sleep Disorder","enrollment":22},{"nctId":"NCT06244823","phase":"PHASE4","title":"The FreMRI Study: Advanced MRI on Migraine Patients Treated With Fremanezumab","status":"UNKNOWN","sponsor":"Hospital Clínico Universitario de Valladolid","startDate":"2023-03-01","conditions":"Migraine Disorders, Migraine With Aura, Migraine Without Aura","enrollment":87},{"nctId":"NCT04461795","phase":"PHASE4","title":"Efficacy of AJOVY (Fremanezumab-vfrm) on Interictal Migraine Related Burden","status":"COMPLETED","sponsor":"David True","startDate":"2020-12-01","conditions":"Migraine","enrollment":40},{"nctId":"NCT04447729","phase":"PHASE2","title":"A Study to Test if Fremanezumab Reduces Pain in Patients With Interstitial Cystitis-Bladder Pain Syndrome","status":"WITHDRAWN","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2020-10-15","conditions":"Interstitial Cystitis","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Fremanezumab Prefilled Syringe","genericName":"Fremanezumab Prefilled Syringe","companyName":"Hospital Clínico Universitario de Valladolid","companyId":"hospital-cl-nico-universitario-de-valladolid","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fremanezumab is a monoclonal antibody that blocks calcitonin gene-related peptide (CGRP), a neuropeptide involved in migraine pathogenesis. Used for Episodic migraine prevention, Chronic migraine prevention.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}